Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

manilatimes.net · 2026-10-23

EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trialThe data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) ('Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.

Read the full story at manilatimes.net →